» Articles » PMID: 34982196

First-line High-dose Therapy and Autologous Blood Stem Cell Transplantation in Patients with Primary Central Nervous System Non-Hodgkin Lymphomas-a Single-centre Experience in 61 Patients

Overview
Journal Ann Hematol
Specialty Hematology
Date 2022 Jan 4
PMID 34982196
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Primary central nervous system non-Hodgkin lymphomas (PCNS-NHLs) are extranodal B-cell lymphomas with poor prognosis. The role of high-dose therapy (HDT) followed by autologous blood stem cell transplantation (ASCT) as first-line therapy is still not clear. We retrospectively collected long-term follow up data of 61 consecutive patients with PCNS-NHL at the University Hospital Düsseldorf from January 2004 to December 2016. Thirty-six patients were treated with conventional chemoimmunotherapy (cCIT) only (CT-group). Seventeen patients received an induction cCIT followed by HDT and ASCT. In the CT-group, the overall response rate (ORR) was 61% (CR 47%, PR 14%), and there were 8% treatment-related deaths (TRD). Progression-free survival (PFS) was 31.8 months, and overall survival (OS) was 57.3 months. In the HDT-group, the ORR was 88% (59% CR, 29% PR), and there were 6% TRD. Median PFS and OS were not reached at 5 years. The 5-year PFS and OS were 64.7%. After a median follow up of 71 months, 10 patients (59%) were still alive in CR/PR following HDT and ASCT, one patient was treated for progressive disease (PD), and 7 had died (41%, 6 PD, 1 TRD). All patients achieving CR prior to HDT achieved durable CR. In the CT-group, 8 patients (22%) were alive in CR/PR after a median follow-up of 100 months. Twenty-eight patients died (78%, 24 PD, 2 TRD, 2 deaths in remission). In the univariate analysis, the HDT-group patients had significantly better PFS (not reached vs 31.8 months, p = 0.004) and OS (not reached vs 57.3 months, p = 0.021). The multivariate analysis showed HDT was not predictive for survival. Treatment with HDT + ASCT is feasible and offers the chance for long-term survival with low treatment-related mortality in younger patients. In this analysis, ORR, PFS and OS were better with HDT than with conventional cCIT alone. This result was not confirmed in the multivariate analysis, and further studies need to be done to examine the role of HDT in PCNSL.

Citing Articles

Functional Outcome and Overall Survival in Patients with Primary or Secondary CNS Lymphoma after Surgical Resection vs. Biopsy.

Staub-Bartelt F, Rittenauer J, Sabel M, Rapp M Cancers (Basel). 2023; 15(21).

PMID: 37958439 PMC: 10647498. DOI: 10.3390/cancers15215266.


A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.

Li Q, Ma Y, Lin Z, Ma J, Kang H, Zhang M J Neurooncol. 2022; 163(1):39-46.

PMID: 35733032 DOI: 10.1007/s11060-022-04062-z.

References
1.
Camilleri-Broet S, Martin A, Moreau A, Angonin R, Henin D, Gontier M . Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS). Am J Clin Pathol. 1998; 110(5):607-12. DOI: 10.1093/ajcp/110.5.607. View

2.
Shibamoto Y, Ogino H, Hasegawa M, Suzuki K, Nishio M, Fujii T . Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005; 62(3):809-13. DOI: 10.1016/j.ijrobp.2004.12.043. View

3.
Ostrom Q, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan J . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020; 22(12 Suppl 2):iv1-iv96. PMC: 7596247. DOI: 10.1093/neuonc/noaa200. View

4.
Ferreri A, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A . A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002; 58(10):1513-20. DOI: 10.1212/wnl.58.10.1513. View

5.
Zhu J, Gerstner E, Engler D, Mrugala M, Nugent W, Nierenberg K . High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2008; 11(2):211-5. PMC: 2718993. DOI: 10.1215/15228517-2008-067. View